Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

2026-02-20 DYSBIOSE CLINCAL STUDY

ABSTRACT: The project aims to identify biomarkers of pulmonary dysbiosis (bacterial, fungal, and viral) associated with exacerbations in people with cystic fibrosis (23 patients). The research plan is organized into four work packages: metagenomics (WP1), metabolomics (WP2), serum inflammatory biomarkers (WP3), and multi-block statistical data integration (WP4). WP1 involves a longitudinal metagenomic analysis of 120 sputum samples collected from the 23 patients across multiple time points (M0 to M18). WP2 focuses on plasma metabolomics using Orbitrap LC-HRMS, with standardized sample preparation, addition of isotopically labeled internal standards, and the use of quality control (QC) samples. In total, 136 plasma samples were analyzed, with sampling every three months over more than 18 months of longitudinal follow-up.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: audrey LE GOUELLEC

PROVIDER: MSV000100923 | MassIVE | Fri Feb 20 14:00:00 GMT 2026

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Contribution of Dysregulated Metabolic Signature in HIV-associated Immune Reconstitution Inflammatory Syndrome

Project description:In this study, we sought to evaluate the metabolic perturbations in IRIS across longitudinal time points using an unbiased plasma metabolomics approach as well as integrated analyses to include plasma inflammatory biomarker profile and whole blood transcriptome

2021-07-01 | GSE173697 | GEO

Non-Small Cell Lung Cancer patients undergoing radical radiotherapy

Project description:Currently there is no predictive marker with clinical utility to guide treatment decisions in NSCLC patients undergoing radiotherapy. Identification of such markers would allow treatment options to be considered for more effective therapy. To enable the identification of appropriate protein biomarkers, plasma samples were collected from patients with non-small cell lung cancer before and during radiotherapy for longitudinal comparison following a protocol that carries sufficient power for effective discovery proteomics. Plasma samples from patients pre- and during radiotherapy who had survived >18 months were compared to the same time points from patients who survived <14 months using an 8 channel isobaric tagging tandem mass spectrometry discovery proteomics platform.

2018-10-19 | PXD001052 | Pride

miRNA signatures derived from plasma small extracellular vesicle as predictors for organo-tropic metastasis of gastric cancer

Project description:Metastasis is a major problem of gastric cancer. In this study, small extracellular vesicle (sEV)-derived miRNAs were sequenced to screen biomarkers for GC’s organo-tropic metastasis. Plasma from 40 treatment-naïve gastric cancer patients including 10 no metastasis (M0) and 30 distant metastasis (M1) were assessed by sEV-miRNA-sequencing. sEV miRNAs with diverse expression profiles across different metastatic patterns were combined into sigantures to characterize and predict gastric cancer metastasis.

2024-06-16 | GSE178283 | GEO

Transcriptomic and metabolomic changes might predict frailty in SAMP8 mice

Project description:Frailty is a geriatric multi-dimensional syndrome which reflects multisystem physiological change and is a transversal measure of reduced resilience to negative events. It is characterized by weakness, frequent falls, cognitive decline, increased hospitalization and dead, and represents a risk factor for the development of Alzheimer’s disease (AD). The fact that frailty is recognized as a reversible condition, encourages the identification of earlier biomarkers to timely predict and prevent its occurrence. SAMP8 (Senescence-Accelerated Mouse Prone-8) mice represent the most appropriate preclinical model to this aim and were used in this study to carry transcriptional and metabolic analyses in the brain and plasma respectively, upon a characterization at cognitive, motor, structural and neuropathological level at 2.5, 6 and 9 months of age. At 2.5 months SAMP8 mice started displaying memory deficits, muscle weakness and motor impairment. Functional alterations were associated with a neurodevelopment deficiency associated with reduced neuronal density and glial cell loss. Through transcriptomics we identified specific genetic signatures well distinguishing SAMP8 mice at 6 months and correlating with motor and cognitive dysfunction, whereas plasma metabolomics allowed to segregate SAMP8 mice from SAMR1 already at 2.5 months of age by detecting constitutively lower levels of acylcarnitines and lipids in SAMP8 at all ages investigated. Our findings suggest that specific genetic alterations at central level, as well as metabolomic changes in plasma, might allow to early assess a frail condition leading to dementia development, which paves the foundation for future investigation in a clinical setting.

2024-11-05 | GSE270589 | GEO

Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.

Project description:The current project was designed to evaluate the utility of proteomics in identifying pharmacodynamic (PD) biomarkers for IL-5 inhibitors mepolizumab and reslizumab. We profiled over 7,000 plasma proteins from longitudinal samples collected from healthy participants treated with mepolizumab (24 mg, n=8), reslizumab (0.8 mg/kg, n=8), or placebo (n=8), and validated findings at lower doses of mepolizumab (12 mg, n=8) and reslizumab (0.4 mg/kg, n=8). We identified eosinophil major basic protein (EMBP) and proteoglycan-3 (PRG3) as promising plasma PD biomarkers, with EMBP responding to mepolizumab and PRG3 to reslizumab treatment. Both biomarkers demonstrated >20% fold change differences versus placebo, achieved statistical significance, and showed dose-response trends and comparable variability to placebo. Our study identified EMBP and PRG3 as promising plasma PD biomarkers for IL-5 inhibitors, warranting further validation for early phase trials and biosimilar development programs.

2026-02-11 | GSE311320 | GEO

Intra-MZ pair discordance and longitudinal variation of whole-genome scale DNA methylation in adults

Project description:In this study, we used Illumina Infinium HumanMethylation450 Beadchips to compare DNA methylation profiles in blood from 10 pairs of MZ twins and 8 individuals recruited at 0, 3, 6, and 9 months. MZ Group (Group A) contained 10 pairs of MZ twins ranging from 23 to 74 years old, including 8 female and 12 male subjects.Longitudinal study group (Group B) included a pair of MZ (male) twins and 6 unrelated individuals (3 male, 3 female), aged from 24 to 39. Except subject H, all participants in Longitudinal study group (Group B) were recalled every 3 months for 9 months (0, 3, 6, and 9 m). Subject H was studied only at 0, 6, and 9 months. Bisulphite converted DNA from the 60 samples were hybridised to the Illumina Infinium 450k Human Methylation Beadchip

2013-10-30 | E-GEOD-51388 | biostudies-arrayexpress

Control Of Major Bleeding After Trauma (COMBAT) Clinical Research Trial

Project description:Denver Health has conducted the Control of Major Bleeding After Trauma (COMBAT) clinical research study, which aimed to improve trauma care for all patients (https://www.denverhealth.org/services/trauma/for-professionals-2/research-publications/combattrial). The study began in April 2014 and concluded in March of 2017. In collaboration with the University of Colorado Anschutz Medical Campus, longitudinal plasma samples collected from the COMBAT trial were analyzed by MS-based proteomics and metabolomics (available on Metabolomics Workbench).

2025-08-25 | PXD053799 | Pride

Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma with Lead-Time Trajectory in Pre-Diagnostic Samples

Project description:Background & Aims: Early detection biomarkers for pancreatic ductal adenocarcinoma (PDAC) are needed since the clinically validated biomarker, CA19-9, has limited sensitivity and specificity for early-stage disease. Circulating miRNAs in plasma associated with cancer relevant pathways were developed as early detection biomarkers. Methods: Whole transcriptome assay interrogated 2,083 miRNAs in 15 µl of plasma from multicenter diagnostic cohorts (N=203: controls, n=82; diagnosed PDAC cases: n=121) and a pre-diagnostic PLCO cohort (N=96; controls, n=48; pre-diagnosed cases, n=48). A three-miRNA biomarker signature was developed for early detection of PDAC. Results: The three-miRNA signature detected PDAC from healthy controls independently (AUC = 0.974) and in combination with CA19-9 (AUC = 0.995). It also discriminated from pancreatitis (AUC = 0.931), improving performance of CA19-9 alone (AUC = 0.749) in combination (AUC = 0.954). Blinded validation in pre-diagnostic PLCO cohort revealed lead-time trajectory increase in AUC to 0.702 tat twelve-months before PDAC diagnosis. Conclusions: Plasma miRNAs associated with oncogenic pathways may serve as PDAC early detection biomarkers, with model performance progressively increasing approximately twelve months before diagnosis.

2026-01-14 | GSE259327 | GEO

Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease

Project description:This study used a trans-omics approach—combining genome-wide SNP analysis and metabolomics—to distinguish coronary artery disease (CAD) patients from high-risk and healthy individuals. It identified declining plasma phospholipids as potential biomarkers, linked key SNPs and genes (notably LPCAT1) to lipid changes, and developed a machine-learning model that accurately predicts CAD (AUC = 0.917). The results highlight the role of phospholipid metabolism and genetic variation in CAD progression.

2025-07-28 | GSE303414 | GEO

miRNA profiles of tubular cells (Rodent A and Rodent B)

Project description:MicroRNAs (miRNAs) are endogenous small RNAs of 18–23 nucleotides that regulate gene expression. Recently, plasma miRNAs have been investigated as biomarkers for various diseases. In the present study, we assessed whether the miRNA expression profiles of tubular tissues could discriminate proximal tubule injury and diagnose acute kidney injury (AKI) and the renal tubular dysfunction without morphological changes.

2015-03-17 | GSE66195 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data